Wang P - Search Results

1

Paraptosis-Inducing Nanomedicine Overcomes Cancer Drug Resistance for a Potent Cancer Therapy.

Zhou Y, Huang F, Yang Y, Wang P, Zhang Z, Tang Y, Shen Y, Wang K. Zhou Y, et al. Among authors: wang k, wang p. Small. 2018 Feb;14(7). doi: 10.1002/smll.201702446. Epub 2018 Jan 19. Small. 2018. PMID: 29350484

2

Aldehyde dehydrogenases and cancer stem cells.

Xu X, Chai S, Wang P, Zhang C, Yang Y, Yang Y, Wang K. Xu X, et al. Among authors: wang k, wang p. Cancer Lett. 2015 Dec 1;369(1):50-7. doi: 10.1016/j.canlet.2015.08.018. Epub 2015 Aug 28. Cancer Lett. 2015. PMID: 26319899 Review.

3

Acute Disseminated Talaromyces marneffei in An Immunocompetent Patient.

Wang P, Chen Y, Xu H, Ding L, Wu Z, Xu Z, Wang K. Wang P, et al. Among authors: wang k. Mycopathologia. 2017 Aug;182(7-8):751-754. doi: 10.1007/s11046-017-0127-7. Epub 2017 Mar 27. Mycopathologia. 2017. PMID: 28349349

4

Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011-2015.

Wang P, Zou J, Wu J, Zhang C, Ma C, Yu J, Zhou Y, Li B, Wang K. Wang P, et al. Among authors: wang k. J Thorac Dis. 2017 Jul;9(7):1973-1979. doi: 10.21037/jtd.2017.06.102. J Thorac Dis. 2017. PMID: 28839996 Free PMC article.

5

Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.

Lan B, Ma C, Zhang C, Chai S, Wang P, Ding L, Wang K. Lan B, et al. Among authors: wang k, wang p. Oncotarget. 2018 Jan 5;9(7):7684-7699. doi: 10.18632/oncotarget.23969. eCollection 2018 Jan 26. Oncotarget. 2018. PMID: 29484144 Free PMC article.

6

Preoperative Risk Assessment of Lymph Node Metastasis in cT1 Lung Cancer: A Retrospective Study from Eastern China.

Zhang C, Pang G, Ma C, Wu J, Wang P, Wang K. Zhang C, et al. Among authors: wang k, wang p. J Immunol Res. 2019 Dec 1;2019:6263249. doi: 10.1155/2019/6263249. eCollection 2019. J Immunol Res. 2019. PMID: 31886306 Free PMC article.

7

The predictive and prognostic effects of PD-L1 expression on TKI treatment and survival of EGFR-mutant NSCLC: A meta-analysis.

Lan B, Wang Y, Wu J, Wang K, Wang P. Lan B, et al. Among authors: wang k, wang y, wang p. Medicine (Baltimore). 2021 Aug 27;100(34):e27038. doi: 10.1097/MD.0000000000027038. Medicine (Baltimore). 2021. PMID: 34449486 Free PMC article.

8

Mefatinib as first-line treatment of patients with advanced EGFR-mutant non-small-cell lung cancer: a phase Ib/II efficacy and biomarker study.

Wang P, Li Y, Lv D, Yang L, Ding L, Zhou J, Hong W, Chen Y, Zhang D, He S, Zhou J, Wang K. Wang P, et al. Among authors: wang k. Signal Transduct Target Ther. 2021 Nov 1;6(1):374. doi: 10.1038/s41392-021-00773-3. Signal Transduct Target Ther. 2021. PMID: 34719670 Free PMC article. Clinical Trial.

9

Construction of a predictive model for immunotherapy efficacy in lung squamous cell carcinoma based on the degree of tumor-infiltrating immune cells and molecular typing.

Yang L, Wei S, Zhang J, Hu Q, Hu W, Cao M, Zhang L, Wang Y, Wang P, Wang K. Yang L, et al. Among authors: wang k, wang y, wang p. J Transl Med. 2022 Aug 12;20(1):364. doi: 10.1186/s12967-022-03565-7. J Transl Med. 2022. PMID: 35962453 Free PMC article.

10

A phase II study on Mefatinib as first-line treatment of patients with advanced non-small-cell lung cancer harboring uncommon EGFR mutations.

Wang P, Cao L, Tian P, Ren S, Miao L, Zhou C, Fan Y, Li Y, Lv D, Zhao X, Yang M, Zhu C, Yu B, Xu J, Song Y, Wang K. Wang P, et al. Among authors: wang k. Cancer Commun (Lond). 2023 Sep;43(9):1059-1063. doi: 10.1002/cac2.12456. Epub 2023 Jun 15. Cancer Commun (Lond). 2023. PMID: 37322852 Free PMC article. Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

43,344 results

Search Page

Filters